Basilea Pharmaceutica (Switzerland) Insiders
| BSLN Stock | CHF 40.90 0.05 0.12% |
Basilea Pharmaceutica employs about 177 people. The company is managed by 10 executives with a total tenure of roughly 413 years, averaging almost 41.0 years of service per executive, having 17.7 employees per reported executive. Recap of Basilea Pharmaceutica's management performance can provide insight into the venture performance.
| Lutz Wevelsiep Insider Head Affairs |
| Adesh Kaul Insider Chief Officer |
Basilea |
Basilea Pharmaceutica Management Team Effectiveness
The company has return on total asset (ROA) of 0.0261 % which means that it generated a profit of $0.0261 on every $100 spent on assets. This is way below average. Basilea Pharmaceutica's management efficiency ratios could be used to measure how well Basilea Pharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Basilea Pharmaceutica Workforce Comparison
Basilea Pharmaceutica AG is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 744. Basilea Pharmaceutica totals roughly 177 in number of employees claiming about 24% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.01 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.06 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.06. Basilea Pharmaceutica Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Basilea Pharmaceutica Price Series Summation is a cross summation of Basilea Pharmaceutica price series and its benchmark/peer.
Basilea Pharmaceutica Notable Stakeholders
A Basilea Pharmaceutica stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Basilea Pharmaceutica often face trade-offs trying to please all of them. Basilea Pharmaceutica's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Basilea Pharmaceutica's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Lutz Wevelsiep | Head Affairs | Profile | |
| Adesh Kaul | Chief Officer | Profile | |
| Damian Heller | Gen Sec | Profile | |
| Gerrit Hauck | Chief Officer | Profile | |
| David Veitch | Chief Officer | Profile | |
| Ursula Eberhardt | Head HR | Profile | |
| Marc MD | Chief Officer | Profile | |
| Peer Schroder | Head Relations | Profile | |
| Dietrich Stber | Head Services | Profile | |
| Laurenz Kellenberger | Chief Officer | Profile |
About Basilea Pharmaceutica Management Performance
The success or failure of an entity such as Basilea Pharmaceutica often depends on how effective the management is. Basilea Pharmaceutica management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Basilea management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Basilea management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company was founded in 2000 and is headquartered in Basel, Switzerland. BASILEA N operates under Pharmaceuticals And Biosciences classification in Switzerland and is traded on Switzerland Exchange. It employs 160 people.
Please note, the imprecision that can be found in Basilea Pharmaceutica's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Basilea Pharmaceutica AG. Check Basilea Pharmaceutica's Beneish M Score to see the likelihood of Basilea Pharmaceutica's management manipulating its earnings.
Basilea Pharmaceutica Workforce Analysis
Traditionally, organizations such as Basilea Pharmaceutica use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Basilea Pharmaceutica within its industry.Basilea Pharmaceutica Manpower Efficiency
Return on Basilea Pharmaceutica Manpower
| Revenue Per Employee | 836.8K | |
| Revenue Per Executive | 14.8M | |
| Net Loss Per Employee | 38.6K | |
| Net Loss Per Executive | 683.1K |
Additional Tools for Basilea Stock Analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.